<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="31941">Oxaliplatin</z:chebi> is first-line chemotherapy for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but produces dose-limiting neurotoxicity </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> neurotoxicity following infusion produces symptoms including cold-triggered <z:hpo ids='HP_0002380'>fasciculations</z:hpo> and cramps, with subsequent <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e> developing at higher cumulative doses </plain></SENT>
<SENT sid="2" pm="."><plain>Axonal excitability studies were undertaken in 15 oxaliplatin-treated patients before and immediately after <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> infusion to determine whether the mechanisms underlying <z:hpo ids='HP_0011009'>acute</z:hpo> neurotoxicity altered resting membrane potential or <z:chebi fb="0" ids="29101">Na(+)</z:chebi>/<z:chebi fb="0" ids="29103">K(+)</z:chebi> pump function </plain></SENT>
<SENT sid="3" pm="."><plain>Excitability properties were assessed before and after maximal voluntary contraction (MVC) of the abductor pollicis brevis </plain></SENT>
<SENT sid="4" pm="."><plain>Following <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> infusion, abnormalities developed in the recovery cycle with refractoriness markedly increased </plain></SENT>
<SENT sid="5" pm="."><plain>Following activity, changes developed consistent with axonal hyperpolarization, with proportional changes pre- and post-<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> in normalized threshold </plain></SENT>
<SENT sid="6" pm="."><plain>However, recovery cycle parameters following activity were significantly and disproportionally enhanced post-<z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>, with partial normalization of the recovery cycle curve post-activity </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with the most abnormal change in the recovery cycle after infusion demonstrated the greatest changes post-contraction </plain></SENT>
<SENT sid="8" pm="."><plain>Prominent abnormalities developed in <z:chebi fb="0" ids="29101">Na(+)</z:chebi> channel-associated parameters in response to natural activity, without significant alteration in axonal membrane potential or <z:chebi fb="0" ids="29101">Na(+)</z:chebi>/<z:chebi fb="0" ids="29103">K(+)</z:chebi> pump function </plain></SENT>
<SENT sid="9" pm="."><plain>Findings from the present series suggest that <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> affects nerve excitability through voltage-dependent mechanisms, with specific effects mediated through axonal <z:chebi fb="0" ids="29101">Na(+)</z:chebi> channel inactivation </plain></SENT>
</text></document>